Predictive and therapeutic implications of a novel PLCy1/SHP2-driven mechanism of cetuximab resistance in metastatic colorectal cancer

Home | Publication | Predictive and therapeutic implications of a novel PLCy1/SHP2-driven mechanism of cetuximab resistance in metastatic colorectal cancer

Publications

75 +

Clinical Trials Ran

0 +

Approved Therapies

Predictive and therapeutic implications of a novel PLCy1/SHP2-driven mechanism of cetuximab resistance in metastatic colorectal cancer

Areas of Expertise

Partnership

Quis volutpat scelerisque quis massa in dolor nunc lectus cursus.